Computed tomography-guided iodine-125 radioactive seed implantation in small-cell lung cancer: A retrospective study.

IF 1.1 4区医学 Q4 ONCOLOGY

Journal of Contemporary Brachytherapy Pub Date : 2022-12-01 DOI:10.5114/jcb.2022.123973

Mengjie Li, Peng Liu, Huan Wang, Biao Wang, Jie Zhou, Yuzhen Jin, Cuicui Wang, Jian Yang, Ping Zhang

{"title":"Computed tomography-guided iodine-125 radioactive seed implantation in small-cell lung cancer: A retrospective study.","authors":"Mengjie Li, Peng Liu, Huan Wang, Biao Wang, Jie Zhou, Yuzhen Jin, Cuicui Wang, Jian Yang, Ping Zhang","doi":"10.5114/jcb.2022.123973","DOIUrl":null,"url":null,"abstract":"Purpose: To explore the efficacy of computed tomography (CT)-guided iodine-125 (125I) radioactive seed implantation for the treatment of small-cell lung cancer (SCLC).Material and methods: A total of 12 SCLC patients were retrospectively enrolled. All patients underwent CT-guided 125I seed implantation therapy, and were followed up until death, the last visit time, or study end time. Primary endpoint was the overall response rate (ORR). Secondary endpoints were local control rate (LCR), progression-free survival (PFS), overall survival (OS), and safety.Results: All patients were successfully implanted with 125I radioactive seeds. The ORR at 2, 6, 12, and 24 months after implantation was 83.3%, 63.6%, 50%, and 40%, respectively; the LCR at 1 and 2 years were 75% (6/8) and 60% (3/5), respectively; the median PFS and OS were 8 and 12 months, respectively; and the OS rate at 6, 12, and 24 months after implantation was 91.67%, 66.67%, and 41.67%, respectively. No surgery-related deaths occurred. During the follow-up period, mild complications were observed in patients, including worsening cough, hemoptysis, and pneumothorax.Conclusions: CT-guided 125I seed implantation therapy is a safe and effective supplementary treatment for SCLC patients, who cannot tolerate radiotherapy.","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":"14 6","pages":"536-541"},"PeriodicalIF":1.1000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/3e/JCB-14-49843.PMC9924147.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Contemporary Brachytherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/jcb.2022.123973","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose: To explore the efficacy of computed tomography (CT)-guided iodine-125 (¹²⁵I) radioactive seed implantation for the treatment of small-cell lung cancer (SCLC).

Material and methods: A total of 12 SCLC patients were retrospectively enrolled. All patients underwent CT-guided ¹²⁵I seed implantation therapy, and were followed up until death, the last visit time, or study end time. Primary endpoint was the overall response rate (ORR). Secondary endpoints were local control rate (LCR), progression-free survival (PFS), overall survival (OS), and safety.

Results: All patients were successfully implanted with ¹²⁵I radioactive seeds. The ORR at 2, 6, 12, and 24 months after implantation was 83.3%, 63.6%, 50%, and 40%, respectively; the LCR at 1 and 2 years were 75% (6/8) and 60% (3/5), respectively; the median PFS and OS were 8 and 12 months, respectively; and the OS rate at 6, 12, and 24 months after implantation was 91.67%, 66.67%, and 41.67%, respectively. No surgery-related deaths occurred. During the follow-up period, mild complications were observed in patients, including worsening cough, hemoptysis, and pneumothorax.

Conclusions: CT-guided ¹²⁵I seed implantation therapy is a safe and effective supplementary treatment for SCLC patients, who cannot tolerate radiotherapy.

Abstract Image

查看原文本刊更多论文

ct引导下碘125放射性粒子植入治疗小细胞肺癌的回顾性研究。

目的:探讨CT引导下碘125 (125I)放射性粒子植入治疗小细胞肺癌(SCLC)的疗效。材料和方法:回顾性纳入12例SCLC患者。所有患者均接受ct引导下的125I粒子植入治疗，并随访至死亡、最后一次就诊时间或研究结束时间。主要终点为总缓解率(ORR)。次要终点是局部控制率(LCR)、无进展生存期(PFS)、总生存期(OS)和安全性。结果:所有患者均成功植入125I放射性粒子。植入后2、6、12、24个月的ORR分别为83.3%、63.6%、50%、40%;1年和2年的LCR分别为75%(6/8)和60% (3/5);中位PFS和OS分别为8个月和12个月;植入后6、12、24个月的总生存率分别为91.67%、66.67%、41.67%。无手术相关死亡发生。随访期间，患者出现轻微并发症，包括咳嗽加重、咯血、气胸。结论:ct引导下的125I粒子植入治疗对于不能耐受放疗的SCLC患者是一种安全有效的辅助治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Contemporary Brachytherapy ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

2.40

自引率

14.30%

发文量

审稿时长

16 weeks

期刊介绍： The “Journal of Contemporary Brachytherapy” is an international and multidisciplinary journal that will publish papers of original research as well as reviews of articles. Main subjects of the journal include: clinical brachytherapy, combined modality treatment, advances in radiobiology, hyperthermia and tumour biology, as well as physical aspects relevant to brachytherapy, particularly in the field of imaging, dosimetry and radiation therapy planning. Original contributions will include experimental studies of combined modality treatment, tumor sensitization and normal tissue protection, molecular radiation biology, and clinical investigations of cancer treatment in brachytherapy. Another field of interest will be the educational part of the journal.